Catumaxomab Market Summary

Key Factors Driving Catumaxomab Growth

1. Re-launch into Europe creates a significant commercial growth opportunity

A major catalyst is the 2025 re-approval of catumaxomab in the EU. The European Commission granted marketing authorization in February 2025, after the original Removab authorization had been withdrawn in 2017 for commercial reasons. This effectively reopens the European market for a therapy with established clinical efficacy. Catumaxomab is currently positioned as the only specifically approved drug therapy for malignant ascites in Europe, giving it strong first-mover differentiation in a condition where treatment has historically relied heavily on repeated drainage.

2. High unmet need and lack of effective pharmacological alternatives

Malignant ascites is a debilitating complication of advanced epithelial cancers, causing abdominal distension, pain, nausea, vomiting and impaired quality of life. Repeated paracentesis remains a major palliative approach, but fluid frequently reaccumulates, requiring repeated hospital/clinical procedures. Published literature describes malignant ascites as an area with limited evidence-based treatment options, making a therapy capable of reducing the need for drainage commercially attractive.

3. Strong clinical evidence for prolonging puncture-free survival

Catumaxomab has a substantial clinical evidence base. In the pivotal randomized Phase II/III study involving 258 patients, catumaxomab significantly prolonged the time patients could remain free from therapeutic paracentesis compared with paracentesis alone. The benefit was particularly evident in patients with gastric cancer. The study concluded that catumaxomab provided a clear clinical benefit with an acceptable safety profile.

Additional clinical data reinforce the symptomatic benefit: in a study of patients with ovarian-cancer-associated malignant ascites, median puncture-free interval increased approximately twofold from 12 to 27.5 days, while time to the next puncture increased approximately fourfold from 12 to 52 days; ascites-related symptoms improved across most predefined symptom categories.

4. Differentiated trifunctional mechanism supports targeted local tumor killing

Catumaxomab has an unusual three-way immune-cell engagement mechanism. One arm binds EpCAM on tumor cells, another binds CD3 on T cells, while the Fc region recruits Fcγ-receptor-positive accessory cells such as macrophages, dendritic cells and NK cells. This simultaneously activates several immune-mediated killing mechanisms, including T-cell-mediated cytotoxicity, ADCC and phagocytosis. Importantly, EpCAM is expressed across many epithelial cancers, including ovarian, gastric, colorectal, pancreatic, lung and breast cancers, supporting its use across multiple causes of malignant ascites.

Catumaxomab Recent Developments

In December 2025, Pharmanovia, a global pharmaceutical company that commercialises novel speciality medicines as well as trusted established medicines, announced the launch of Catumaxomab in Germany, making the T-cell engager trifunctional antibody medicine the first and only pharmacological treatment available for malignant ascites (MA) for people living with this debilitating condition within the region.

“Catumaxomab Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Catumaxomab for approved indication like Malignant ascites; as well as potential indication like Gastric cancer and Bladder cancer in the 7MM. A detailed picture of Catumaxomab’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Catumaxomab for approved and potential indications. The Catumaxomab market report provides insights about Catumaxomab’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Catumaxomab performance, future market assessments inclusive of the Catumaxomab market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Catumaxomab sales forecasts, along with factors driving its market.

Catumaxomab Drug Summary

Catumaxomab is a trifunctional bispecific monoclonal antibody developed for the treatment of malignant ascites associated with EpCAM-positive epithelial carcinomas. The drug simultaneously targets epithelial cell adhesion molecule (EpCAM) expressed on tumor cells and CD3 on T cells, while its Fc region interacts with Fc-gamma receptors on accessory immune cells such as macrophages, natural killer cells, and dendritic cells. This mechanism brings tumor cells and immune effector cells into close proximity, promoting T-cell-mediated tumor-cell lysis, antibody-dependent cellular cytotoxicity, and phagocytosis, thereby reducing tumor burden within the peritoneal cavity and helping control the accumulation of malignant ascites. Catumaxomab is administered intraperitoneally by infusion, traditionally as a four-dose regimen, and was initially marketed in the European Union as Removab following approval in 2009. The earlier Removab authorization was withdrawn in 2017 for commercial reasons; subsequently, catumaxomab was reauthorized in the EU under the brand Korjuny, with authorization issued in February 2025 for adults with EpCAM-positive malignant ascites who are not eligible for further systemic anticancer therapy. The report provides Catumaxomab’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Catumaxomab Market Report

The report provides insights into:

• A comprehensive product overview including the Catumaxomab MoA, description, dosage and administration, research and development activities in approved indications like Malignant ascites; as well as potential indication like Gastric cancer and Bladder cancer.
• Elaborated details on Catumaxomab regulatory milestones and other development activities have been provided in Catumaxomab market report.
• The report also highlights Catumaxomab‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Catumaxomab market report also covers the patents information, generic entry and impact on cost cut.
• The Catumaxomab market report contains current and forecasted Catumaxomab sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Catumaxomab market report also features the SWOT analysis with analyst views for Catumaxomab in approved and potential indications.

Methodology

The Catumaxomab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Catumaxomab Analytical Perspective by DelveInsight

• In-depth Catumaxomab Market Assessment

This Catumaxomab sales market forecast report provides a detailed market assessment of Catumaxomab for approved indication like Malignant ascites; as well as potential indication like Gastric cancer and Bladder cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Catumaxomab sales data uptil 2034.

• Catumaxomab Clinical Assessment

The Catumaxomab market report provides the clinical trials information of Catumaxomab for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Catumaxomab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Catumaxomab Market Potential & Revenue Forecast

• Projected market size for the Catumaxomab and its key indications
• Estimated Catumaxomab sales potential (Catumaxomab peak sales forecasts)
• Catumaxomab Pricing strategies and reimbursement landscape

Catumaxomab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Catumaxomab Market positioning compared to existing treatments
• Catumaxomab Strengths & weaknesses relative to competitors

Catumaxomab Regulatory & Commercial Milestones

• Catumaxomab Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Catumaxomab Clinical Differentiation

• Catumaxomab Efficacy & safety advantages over existing drugs
• Catumaxomab Unique selling points

Catumaxomab Market Report Highlights

• In the coming years, the Catumaxomab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Catumaxomab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Catumaxomab’s dominance.
• Other emerging products for Malignant ascites; as well as potential indication like Gastric cancer and Bladder cancer are expected to give tough market competition to Catumaxomab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Catumaxomab in approved and potential indications.
• Analyse Catumaxomab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Catumaxomab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Catumaxomab in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Catumaxomab? How strong is Catumaxomab’s clinical and commercial performance?
• What is Catumaxomab’s clinical trial status in each individual indications such as Malignant ascites; as well as potential indication like Gastric cancer and Bladder cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Catumaxomab Manufacturers?
• What are the key designations that have been granted to Catumaxomab for approved and potential indications? How are they going to impact Catumaxomab’s penetration in various geographies?
• What is the current and forecasted Catumaxomab market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Catumaxomab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Catumaxomab for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Catumaxomab? What is the duration of therapy and what are the geographical variations in cost per patient?